Infigratinib phosphate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2021
- First approval year
- 2021
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Infigratinib phosphate
- Molecular weight
- 658.48
- Structure (SMILES)
- CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O
- truseltiq
- Truseltiq
- bgj 398 phosphate
- BGJ-398 phosphate
- infigratinib monophosphate
- Infigratinib monophosphate
- infigratinib phosphate
- Infigratinib phosphate
- Infigratinib phosphate [MI]
- INFIGRATINIB PHOSPHATE [ORANGE BOOK]
- INFIGRATINIB PHOSPHATE [USAN]
- Infigratinib phosphate [WHO-DD]
- infigratinib phosphate mi
- infigratinib phosphate orange book
- infigratinib phosphate usan
- infigratinib phosphate who dd
- n 2 6 dichloro 3 5 dimethoxyphenyl n 6 4 4 ethylpiperazin 1 yl anilino pyrimidin 4 yl n methylurea phosphate 1 1
- N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-(4-(4-ETHYLPIPERAZIN-1-YL)ANILINO)PYRIMIDIN-4-YL)-N-METHYLUREA PHOSPHATE (1:1)
- ATC classification codes
- L01EN03
Sources for recorded values
- CAS registry numbers
- 1310746-10-1
- ChEMBL ID
- CHEMBL1834657
- InChIKey
- GUQNHCGYHLSITB-UHFFFAOYSA-N
- PubChem compound IDs
- 56669626
- RxNorm IDs (RxCUI)
- 2550729
- FDA ingredient codes (UNII)
- 58BH47BV6S
- Applicant
- HELSINN HLTHCARE
- Approval date
- 28 May 2021
- Application number
- NDA214622
- Patents
- 4
- Designations
- 0
- Earliest recorded loss of exclusivity
- 11 Dec 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- discontinued
- Drug name stem
- -tinib
Administration routes
- Oral
- Mechanism
- Fibroblast growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor receptor
- Protein identifier
- P11362
- Mechanism
- Fibroblast growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor receptor
- Protein identifier
- P21802
- Mechanism
- Fibroblast growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor receptor
- Protein identifier
- P22455
- Mechanism
- Fibroblast growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor receptor
- Protein identifier
- P22607
Open Targets mechanisms
- Mechanism
- Fibroblast growth factor receptor inhibitor
- Action type
- Inhibitor
- Target
- Fibroblast growth factor receptor
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001961
- Subject identifier
- D018281
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0005221
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0019087
- Highest recorded phase
- 4
Reported adverse events
- Event
- hyperphosphataemia
- Reports
- 3
- Reporting signal score
- 22.6815
Trial references
- NCT05514912
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 95.09
- Calculated partition coefficient (ALogP)
- 5.35
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 43
- Molecular formula
- C26H34Cl2N7O7P
- Monoisotopic mass
- 657.1634388
- Natural product
- No
- Recorded assays
- 193
- Active assays
- 59
Active assay types
- Confirmatory
Oral bioavailability
- Median
- 41.5
- Mean
- 41.5
- Minimum
- 32
- Maximum
- 51
- Unit
- %
- Assays
- 2
- Standard deviation
- 13.435
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (17)
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
- An Interventional Study of Infigratinib in Children With Hypochondroplasia
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)
- Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations
- Infigratinib in Recurrent High-Grade Glioma Patients
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- Phase I BLASST-3 Trial
- Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
- Study of Infigratinib in Children With Achondroplasia
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations
Approved for (2)
- Cholangiocarcinoma
- Intrahepatic cholangiocarcinoma
In development for (1)
- Neoplasm Phase 1